AstraZeneca today announced a major acquisition of its cholesterol-lowering cholesterol drug Crestor from Mylan Inc. The deal for Crestor will provide AstraZeneca with an upfront payment of $1.45 billion for the remaining market share. The upfront payment will be based on a reported consensus of $2.50 billion, and will be subject to future market adjustments and future costs.
In a press release, AstraZeneca noted that “the acquisition of Mylan offers AstraZeneca a new and competitive market opportunity for Crestor, a widely used and effective treatment for patients with cholesterol and triglycerides abnormalities.”
“The acquisition of Crestor provides AstraZeneca with a new opportunity to further strengthen its market position in the treatment of high-risk patients,” stated Mylan President and Chief Executive Officer Michael L. Smith.
“We are pleased to be leading the way in managing our existing cholesterol-lowering drug portfolio,” said AstraZeneca president and chief executive officer David R. Johnson.
“As we continue our pursuit of new therapies for patients with these conditions, we are delighted to partner with Mylan. Our recent acquisition of Crestor marks a significant milestone in our long-term strategy for this important class of cholesterol-lowering drugs,” said John J. Kilborn, AstraZeneca’s Chief Executive Officer.
About AstraZeneca
AstraZeneca is the world’s leading provider of generic, branded and specialty branded medicines. With a strong focus on innovative research and development, we are committed to providing our patients with high-quality, effective medicines to improve quality of life and enhance quality of life for millions of patients worldwide.
We are a member of the G. O. P. (generic pharmacy benefit organization) (PRA) drug benefit system, an industry-leading, global organization that provides health care reform and patient care to more than 22 countries. For more than 50 years, AstraZeneca has been serving patients with high-risk cholesterol.
Our mission is to bring innovative medicines to people who need them most. For more information, please visit: www.astrazeneca.com
For more information about our products, please visit our website at www.astrazeneca.com.
Contact:
Michael L. Smith, +1-746-543-2540, [email protected]
SOURCE AstraZeneca
Investor's GuideCiphex Pharmaceuticals LtdInvestor’s GuideView shareholder’s GuideInvestors' Guide
References
1. Crestor, AstraZeneca Pharmaceuticals, Inc. (“CE”), 6/23/2022, p. 2
Ciphex, AstraZeneca Pharmaceuticals, Inc. 4
Crestor, Crestor, Inc.
3/12/2022, p. 132. Crestor, AstraZeneca Pharmaceuticals, Inc., 6/23/2022, p. 16
3. AstraZeneca, AstraZeneca Pharmaceuticals, Inc. 21
4.
CRESTOR 40MG TABLET is used in the management of high blood cholesterol levels. It is prescribed when diet and exercise does not result in adequate results. It contains a medicine called which is an anti-hyperlipidemic agent that works by blocking cholesterol production in the body. It also makes your body eliminate lipids particles from the blood.
By reducing blood cholesterol levels, this medicine is helpful is reducing cardiovascular risks and problems in blood circulation across the body. While taking CRESTOR 40MG TABLET, you must follow a cholesterol-lowering diet, lifestyle changes and regular physical activity as instructed by your doctor to achieve better results.
Before taking CRESTOR 40MG TABLET inform your doctor if you have any lung, liver, kidney or heart problems. You must also inform your doctor if you have diabetes, thyroid problems, or a family history of muscle disorders. Do not take CRESTOR 40MG TABLET if you are pregnant or breastfeeding without consulting your doctor.
CRESTOR 40MG TABLET may increase your blood sugar levels, especially in patients who are diabetic. It may also affect the way your liver works and so your doctor will closely monitor your blood sugar levels and liver functions while undergoing therapy with CRESTOR 40MG TABLET as a precaution.
The most common side effects of taking CRESTOR 40MG TABLET are muscle ache, constipation, stomach pain, dizziness, nausea and headache. Inform your doctor if you experience severe unexplained muscle pain, tenderness or weakness along with fever after taking CRESTOR 40MG TABLET.
How should I take CRESTOR 40MG TABLET? The usual dose of CRESTOR 40MG TABLET is 5 or 10mg once daily. The maximum recommended dose is CRESTOR 10mg once daily. The role of a healthcare professional is to monitor your blood sugar levels and liver functions while you take CRESTOR 40MG TABLET as a precaution while also takingte probact medicine (the medicine used to treat liver problems is also used to lower blood sugar levels by selling it as CRESTOR 10).The recommended dose of CRESTOR 40MG TABLET for adults is 10mg once daily. The maximum daily dose is 40mg.
reliever medication for the treatment of hyperlipidemia is CRESTOR 10mg. You should avoid consuming grapefruit juice or grapefruit juice-containing products before taking CRESTOR 10mg as they may affect the medicine's effectiveness.
The maximum recommended dose of reliever medication is CRESTOR 20mg twice daily. Patients with renal failure have difficulty taking the medicine so there may be low levels of the medicine in your blood.
What should I do if I miss taking a dose of CRESTOR 40MG TABLET? If you miss a dose of CRESTOR 40MG TABLET, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not take a double dose to make up for the missed dose. Do not take a double dose of CRESTOR 40MG TABLET or any reliever medication if you are prescribed it twice daily.Possible but major impact of CRESTOR 40MG TABLET in the treatment of hyperlipidemia is the reduction in total cholesterol and high density lipatients cholesterol levels. These changes may lead to reversal of effect.
By Linda A. Bess
When a prescription drugmaker announced the proposed merger of Crestor, a heart drug maker that was once a household name, it gave the drugmaker a second head-of-trade to manage the market.
The deal, which was announced by its chairman and chief executive, Dr. Michael Pearson, comes after the drugmaker received final approval from the U. S. Food and Drug Administration for the drug in 2011.
It would have been the first step in achieving regulatory approval of a heart drug, but its current head-of-trade, Crestor, is still not ready to take over the drugmaker's marketing and sales practices.
The drugmaker had planned to buy the drug from Pfizer, a US drug company that manufactures Crestor and Crestor XR, to make it the go-to drug for a large number of consumers and their doctors.
But the merger brought a major challenge for Pfizer, which had been under fire for years for selling the drug to doctors for a fraction of the cost of other heart drugs, and for a lack of oversight in its sales and marketing.
The drugmaker said in April it would seek FDA approval to make a similar deal with the United States Food and Drug Administration. It also sought approval from the agency in January to market Crestor as an off-label use of a drug.
Pfizer said it would work with the FDA to approve the deal, which was approved in July. Pfizer also was considering the merger and would consider other options including selling the drug to patients who already have it, such as a new company to manage marketing and sales.
In May, the company announced it would cut the Crestor price of $10 per pill and the brand name of the drug in half. It also withdrew from marketing and sales the drug from a number of other companies.
Pfizer said in a statement that it would seek FDA approval to market the drug at a lower price than the cost of the other competitors.
The two companies have already announced their plans for marketing the drug, though the deal with Crestor was not finalized until late this month, when Pfizer will seek FDA approval to market the drug.
The proposed merger, which is expected to close in late March, was approved in August, with Pfizer saying it will take over the remaining marketing and sales of Crestor and other generic drugs. It is likely that other drugmakers will take up the remaining marketing and sales of Crestor.
The company has previously stated that it would not take a charge to make a merger with Pfizer.
A spokesperson for Pfizer said that it was "very disappointed" with the proposed merger, which was approved in May and is expected to close in March.
The drugmaker will retain the brand name of Crestor and will pay out $500 million to buy the company from other manufacturers.
The new company will own its rights to Crestor, including the exclusive right to sell the drug from a different company.
The company is also planning to market a generic version of Crestor, which it says is already manufactured by another company.
The company has also said it will offer Crestor at a cheaper rate, including at a discount to the brand name price, while it will only be available for consumers who buy the drug at a lower price than the brand name, the company said. The drugmaker said it will also be able to sell Crestor at a lower price than the brand name, but at a cheaper rate than the brand name.
It also said it has the option to acquire the rights to generic Crestor through a joint venture with GlaxoSmithKline.
Pfizer, the drugmaker, has been the subject of criticism for the proposed merger.
The company said it would also pay out $2 billion to settle civil lawsuits related to the alleged sales of Crestor, which it said had been linked to "substantial" risks, including increased costs and higher rates of price competition, and that the drug was not "implemented with the proper science, with the proper technology, and with the appropriate care and skill."
The company also said it would pay out $1.5 billion to settle a number of other lawsuits over the sale of Crestor, which it said had been linked to a "substantial" risk.
The company's share price, which will be at a premium, rose 8 percent to $21.99 in the first quarter. The drugmaker said the increased price came on the heels of its decision to close in January.
Crestor (Rosuvastatin) is a statin drug that helps reduce LDL (bad cholesterol) and triglycerides and certain risk factors such as certain types of cancer and heart disease in people with high levels of these lipids. People with high levels of these lipids may have heart disease, stroke, high blood pressure, diabetes, certain high blood sugar conditions and/or conditions, and/or have a tendency to develop a condition which causes the heart muscle to beat more quickly and to produce creatine phosphokinin (an enzyme which helps reduce blood sugar levels).
Crestor has been shown to decrease the amount of cholesterol made by the liver and increase the amount of triglycerides made by the body. People with cholesterol levels above the upper recommended limit may have a very high risk of heart disease and/or stroke.
The Food and Drug Administration (FDA) has approved Crestor for people with cholesterol levels between 170 and 185 mg/dl, people with high cholesterol levels between 100 and 154 mg/dL, people with a tendency to develop a condition which causes the heart muscle to beat more quickly and to produce creatine phosphokinin (an enzyme which helps reduce blood sugar levels).
People who have high cholesterol levels (at least 325 mg/dL) should be prescribed an oral medication that decreases the risk of heart disease, stroke and other related conditions. People who have coronary artery disease (CAD) or other conditions which increase the risk of heart attack or stroke should be prescribed a statin drug which decreases the risk of developing these conditions. People who are or who are about to have a heart attack or stroke should speak with their doctor before starting a statin drug.
Rosuvastatin (the generic name for Crestor) is a statin which is used to lower cholesterol and triglycerides and reduce the risk of developing a condition which increases the risk of heart disease and/or stroke. Crestor is available in tablet form and also as an oral tablet.
Rosuvastatin and Crestor: How Effective Are They?Rosuvastatin is the generic name for Crestor.It is the active ingredient in Crestor. People with high levels of cholesterol, triglycerides and certain other risk factors should use Crestor as directed by a doctor. People who have certain types of cancer, diabetes and other conditions should use Crestor as directed by a doctor.
Crestor is a prescription drug. It is used for the treatment of certain types of high cholesterol, a condition known as high blood pressure. The drug was approved by the FDA in 2003 and was approved by the United States Food and Drug Administration (USFDA) in 2014. The drug is available in tablet form and as a nasal spray or nasal spray-based nasal spray-based solution. Crestor is also approved to be used off-label for the prevention of certain types of cancer.
It is available in tablet form and as a nasal spray or nasal spray-based solution.
Crestor is an antacid medication. It is used to treat stomach problems, such as gastritis, heartburn and ulcers. The drug is available in capsules and can be prescribed by doctors for adults and children over the age of 12. The antacid is a non-steroidal anti-inflammatory drug (NSAID). It can be taken by mouth or applied to the skin.
The drug is available in tablet form and as a nasal spray or nasal spray-based solution.
It is used to treat certain types of high cholesterol, a condition known as high blood pressure.
Stade de France Pharmacy